{
    "startDate": "2019-01-01",
    "endDate": "2019-09-30",
    "year": "2019",
    "quarter": "Q3",
    "symbol": "BBIO",
    "data": {
        "bs": [
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 413973000
            },
            {
                "label": "Short-term marketable securities",
                "concept": "MarketableSecuritiesCurrent",
                "unit": "usd",
                "value": 122080000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "PrepaidExpenseAndOtherAssetsCurrent",
                "unit": "usd",
                "value": 22102000
            },
            {
                "label": "Current assets:",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 558155000
            },
            {
                "label": "Property and equipment, net",
                "concept": "PropertyPlantAndEquipmentNet",
                "unit": "usd",
                "value": 2984000
            },
            {
                "label": "Long-term marketable securities",
                "concept": "MarketableSecuritiesNoncurrent",
                "unit": "usd",
                "value": 75886000
            },
            {
                "label": "PellePharm investment",
                "concept": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
                "unit": "usd",
                "value": 907000
            },
            {
                "label": "Other assets",
                "concept": "OtherAssetsNoncurrent",
                "unit": "usd",
                "value": 2598000
            },
            {
                "label": "Assets",
                "concept": "Assets",
                "unit": "usd",
                "value": 640530000
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 10270000
            },
            {
                "label": "Accrued compensation and benefits",
                "concept": "EmployeeRelatedLiabilitiesCurrent",
                "unit": "usd",
                "value": 7580000
            },
            {
                "label": "Accrued research and development liabilities current.",
                "concept": "bbio:AccruedResearchAndDevelopmentLiabilitiesCurrent",
                "unit": "usd",
                "value": 13198000
            },
            {
                "label": "LEO call option liability current.",
                "concept": "bbio:LEOCallOptionLiabilityCurrent",
                "unit": "usd",
                "value": 4021000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 4789000
            },
            {
                "label": "Current liabilities:",
                "concept": "LiabilitiesCurrent",
                "unit": "usd",
                "value": 39858000
            },
            {
                "label": "Term loans, noncurrent",
                "concept": "LongTermDebtNoncurrent",
                "unit": "usd",
                "value": 75017000
            },
            {
                "label": "Other liabilities",
                "concept": "OtherLiabilitiesNoncurrent",
                "unit": "usd",
                "value": 1388000
            },
            {
                "label": "Current liabilities:",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 116263000
            },
            {
                "label": "Commitments and contingencies (Note 10)",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Redeemable convertible noncontrolling interests",
                "concept": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
                "unit": "usd",
                "value": 2570000
            },
            {
                "label": "Undesignated preferred stock, $0.001 par value; 25,000,000 and no shares authorized as of September 30, 2019 and December 31, 2018; no shares issued and outstanding as of September 30, 2019 and December 31, 2018",
                "concept": "PreferredStockValue",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "Common stock, $0.001 par value; 500,000,000 and 97,412,870 shares authorized as of September 30, 2019 and December 31, 2018; 117,359,502 and 92,057,704 shares issued and outstanding as of September 30, 2019 and December 31, 2018",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 117000
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapitalCommonStock",
                "unit": "usd",
                "value": 826062000
            },
            {
                "label": "Accumulated other comprehensive income",
                "concept": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
                "unit": "usd",
                "value": 152000
            },
            {
                "label": "Accumulated deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -366573000
            },
            {
                "label": "Stockholders\u2019 equity:",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": 459758000
            },
            {
                "label": "Noncontrolling interests",
                "concept": "MinorityInterest",
                "unit": "usd",
                "value": 61939000
            },
            {
                "label": "Total stockholders' equity",
                "concept": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": 521697000
            },
            {
                "label": "Total liabilities, redeemable convertible noncontrolling interests and stockholders\u2019 equity",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 640530000
            }
        ],
        "cf": [
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -204434000
            },
            {
                "label": "Depreciation and amortization",
                "concept": "DepreciationAndAmortization",
                "unit": "usd",
                "value": 618000
            },
            {
                "label": "Net accretion and amortization of premium and discounts on marketable securities",
                "concept": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
                "unit": "usd",
                "value": 69000
            },
            {
                "label": "Equity-based compensation",
                "concept": "ShareBasedCompensation",
                "unit": "usd",
                "value": 11367000
            },
            {
                "label": "Loss on disposal of property and equipment, net",
                "concept": "GainLossOnSaleOfPropertyPlantEquipment",
                "unit": "usd",
                "value": -63000
            },
            {
                "label": "Business combination loss on asset acquisitions.",
                "concept": "bbio:BusinessCombinationLossOnAssetAcquisitions",
                "unit": "usd",
                "value": 416000
            },
            {
                "label": "Loss from PellePharm",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -16144000
            },
            {
                "label": "Accretion of term loans and convertible promissory notes",
                "concept": "AccretionExpense",
                "unit": "usd",
                "value": 722000
            },
            {
                "label": "Acquired in-process research and development assets",
                "concept": "ResearchAndDevelopmentInProcess",
                "unit": "usd",
                "value": 3560000
            },
            {
                "label": "Shares issued under license agreement.",
                "concept": "bbio:SharesIssuedUnderLicenseAgreement",
                "unit": "usd",
                "value": 220000
            },
            {
                "label": "Call option expense.",
                "concept": "bbio:CallOptionExpense",
                "unit": "usd",
                "value": 1012000
            },
            {
                "label": "Prepaid expenses and other current assets",
                "concept": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
                "unit": "usd",
                "value": 12541000
            },
            {
                "label": "Other assets",
                "concept": "IncreaseDecreaseInOtherOperatingAssets",
                "unit": "usd",
                "value": 1664000
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": -3239000
            },
            {
                "label": "Accrued compensation and benefits",
                "concept": "IncreaseDecreaseInEmployeeRelatedLiabilities",
                "unit": "usd",
                "value": 3533000
            },
            {
                "label": "Increase (decrease) in accrued research and development liabilities.",
                "concept": "bbio:IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities",
                "unit": "usd",
                "value": 4284000
            },
            {
                "label": "Other accrued liabilities",
                "concept": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
                "unit": "usd",
                "value": 2689000
            },
            {
                "label": "Other liabilities",
                "concept": "IncreaseDecreaseInOtherOperatingLiabilities",
                "unit": "usd",
                "value": -65000
            },
            {
                "label": "Operating activities:",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -177384000
            },
            {
                "label": "Purchases of marketable securities",
                "concept": "PaymentsToAcquireMarketableSecurities",
                "unit": "usd",
                "value": 197745000
            },
            {
                "label": "Cash paid for in-process research and development assets acquired",
                "concept": "PaymentsToAcquireInProcessResearchAndDevelopment",
                "unit": "usd",
                "value": 2500000
            },
            {
                "label": "Cash and cash equivalents acquired in ML Bio asset acquisition",
                "concept": "CashAcquiredFromAcquisition",
                "unit": "usd",
                "value": 784000
            },
            {
                "label": "Purchases of property and equipment",
                "concept": "PaymentsToAcquirePropertyPlantAndEquipment",
                "unit": "usd",
                "value": 891000
            },
            {
                "label": "Investing activities",
                "concept": "NetCashProvidedByUsedInInvestingActivities",
                "unit": "usd",
                "value": -200352000
            },
            {
                "label": "Proceeds from issuance of common stock in connection with the initial public offering, net of underwriting discounts and commissions",
                "concept": "ProceedsFromIssuanceInitialPublicOffering",
                "unit": "usd",
                "value": 366237000
            },
            {
                "label": "Stock Issued No Premium",
                "concept": "bbio:StockIssuedNoPremium",
                "unit": "usd",
                "value": 23309000
            },
            {
                "label": "Proceeds from repayment of nonrecourse notes",
                "concept": "ProceedsFromRepaymentsOfSecuredDebt",
                "unit": "usd",
                "value": 179000
            },
            {
                "label": "Proceeds from term loans, net of issuance costs",
                "concept": "ProceedsFromDebtNetOfIssuanceCosts",
                "unit": "usd",
                "value": 19787000
            },
            {
                "label": "Proceeds from third party investors in redeemable convertible noncontrolling interests.",
                "concept": "bbio:ProceedsFromThirdPartyInvestorsInRedeemableConvertibleNoncontrollingInterests",
                "unit": "usd",
                "value": 1500000
            },
            {
                "label": "MyoKardia distributions (Note 15)",
                "concept": "PaymentsOfDividends",
                "unit": "usd",
                "value": 997000
            },
            {
                "label": "Repurchase of noncontrolling interest",
                "concept": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
                "unit": "usd",
                "value": 55011000
            },
            {
                "label": "Proceeds from subsidiary stock options exercises.",
                "concept": "bbio:ProceedsFromSubsidiaryStockOptionsExercises",
                "unit": "usd",
                "value": 884000
            },
            {
                "label": "Financing activities",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 355888000
            },
            {
                "label": "Net increase (decrease) in cash, cash equivalents and restricted cash",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
                "unit": "usd",
                "value": -21848000
            },
            {
                "label": "Cash paid for interest",
                "concept": "InterestPaidNet",
                "unit": "usd",
                "value": 4336000
            },
            {
                "label": "Tenant improvement paid by landlord",
                "concept": "PaymentsForTenantImprovements",
                "unit": "usd",
                "value": 959000
            },
            {
                "label": "Transfers to (from) non-controlling interest.",
                "concept": "bbio:TransfersToFromNonControllingInterest",
                "unit": "usd",
                "value": 41937000
            }
        ],
        "ic": [
            {
                "label": "License revenue",
                "concept": "RevenueFromContractWithCustomerExcludingAssessedTax",
                "unit": "usd",
                "value": 26741000
            },
            {
                "label": "Cost of license revenue.",
                "concept": "bbio:CostOfLicenseRevenue",
                "unit": "usd",
                "value": 2500000
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 152462000
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 59381000
            },
            {
                "label": "Operating expenses:",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 214343000
            },
            {
                "label": "Loss from operations",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -187602000
            },
            {
                "label": "Interest income",
                "concept": "InvestmentIncomeInterest",
                "unit": "usd",
                "value": 6505000
            },
            {
                "label": "Interest expense",
                "concept": "InterestExpense",
                "unit": "usd",
                "value": 5725000
            },
            {
                "label": "Business combination loss on asset acquisitions.",
                "concept": "bbio:BusinessCombinationLossOnAssetAcquisitions",
                "unit": "usd",
                "value": 416000
            },
            {
                "label": "Loss from PellePharm",
                "concept": "IncomeLossFromEquityMethodInvestments",
                "unit": "usd",
                "value": -16144000
            },
            {
                "label": "LEO call option income (expense)",
                "concept": "FairValueOptionChangesInFairValueGainLoss1",
                "unit": "usd",
                "value": -1012000
            },
            {
                "label": "Other income (expense)",
                "concept": "OtherNonoperatingIncomeExpense",
                "unit": "usd",
                "value": -40000
            },
            {
                "label": "Other income (expense), net:",
                "concept": "NonoperatingIncomeExpense",
                "unit": "usd",
                "value": -16832000
            },
            {
                "label": "Net loss",
                "concept": "ProfitLoss",
                "unit": "usd",
                "value": -204434000
            },
            {
                "label": "Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests",
                "concept": "NetIncomeLossAttributableToNoncontrollingInterest",
                "unit": "usd",
                "value": -17305000
            },
            {
                "label": "Net loss attributable to common stockholders of BridgeBio",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -187129000
            },
            {
                "label": "Net loss per share, basic and diluted",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": -1.86
            },
            {
                "label": "Weighted-average shares used in computing net loss per share, basic and diluted",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 100855481
            },
            {
                "label": "Unrealized gain on available-for-sale securities",
                "concept": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
                "unit": "usd",
                "value": 152000
            },
            {
                "label": "Comprehensive loss",
                "concept": "ComprehensiveIncomeNetOfTax",
                "unit": "usd",
                "value": -204282000
            }
        ]
    }
}